Samsom, Kris G.
Bosch, Linda J. W.
Schipper, Luuk J.
Schout, Daoin
Roepman, Paul
Boelens, Mirjam C.
Lalezari, Ferry
Klompenhouwer, Elisabeth G.
de Langen, Adrianus J.
Buffart, Tineke E.
van Linder, Berit M. H.
van Deventer, Kelly
van den Burg, Kay
Unmehopa, Unga
Rosenberg, Efraim H. http://orcid.org/0000-0002-3859-6941
Koster, Roelof http://orcid.org/0000-0003-1424-8579
Hogervorst, Frans B. L.
van den Berg, José G.
Riethorst, Immy
Schoenmaker, Lieke
van Beek, Daphne
de Bruijn, Ewart
van der Hoeven, Jacobus J. M.
van Snellenberg, Hans
van der Kolk, Lizet E.
Cuppen, Edwin http://orcid.org/0000-0002-0400-9542
Voest, Emile E. http://orcid.org/0000-0001-8249-9586
Meijer, Gerrit A. http://orcid.org/0000-0003-0330-3130
Monkhorst, Kim
Article History
Received: 20 June 2022
Accepted: 19 October 2023
First Online: 13 December 2023
Competing interests
: A.J.d.L. reports grants from Bristol Myers Squibb (BMS), Merck Sharp & Dohme (MSD), AstraZeneca and Boehringer, nonfinancial support from Merck Serono and Roche. H.v.S. and E.C. report consultancy fees and support for attending meetings and travelling from Illumina. E.E.V. is a member of the supervisory board of Hartwig. G.A.M. is co-founder and board member (CSO) of CRCbioscreen, he has a research collaboration with CZ Health Insurances (cash matching to ZonMW grant) and has research collaborations with Exact Sciences, Sysmex, Sentinel Ch. SpA, Personal Genome Diagnostics and DELFi; these companies provide materials, equipment and/or sample/genomic analyses. G.A.M. is an advisory board member of ‘Missie Tumor Onbekend’. K.M. reports research grants from AstraZeneca and speakers’ fees from MSD, Roche, AstraZeneca and Benecke. K.M. received consultancy fees from Pfizer, BMS, Roche, MSD, Abbvie, AstraZeneca, Diaceutics, Lilly, Bayer, Boehringer and Ingelheim and nonfinancial support from Roche, Takeda, Pfizer, PGDx and DELFi. The remaining authors report no conflicts of interest.